Back to Portfolio

Memo Therapeutics

Fighting diseases with human-derived monoclonal antibodies
 
Memo Therapeutics

Antibodies are our immune system's most sophisticated weapon against diseases and represent highly promising therapeutics against a wide range of conditions. Memo Therapeutics has developed a platform enabling for the first time the extraction, banking and production of human-derived monoclonal antibodies. By making the complete antibody repertoire of an individual available, this versatile platform allows extremely cost- and time-efficient generation of therapeutic antibodies against new and difficult disease targets.


Homepage      

 

Memo in the News: 

Redalpine leads Series A for groundbreaking antibody discovery company